glp 1 and cognitive function Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Decline Dementia in Diabetes Mellitus Frontiers | Effect and mechanism
Description
The work is mainly aimed at boosting efficacy, making patient convenience a bit easier, and pushing therapeutic use beyond diabetes management, like more metabolic needs
CVS Caremark negotiated a deal with Novo Nordisk (Wegovy's manufacturer) that made Wegovy the preferred GLP-1 medication starting July 2025
Legitimacy and Regulatory Oversight What regulatory standards apply to each option
Finally, the 3/6/9/12 mg group received 3 mg for the first two weeks, 6 mg for weeks 34, 9 mg for weeks 58, and 12 mg for weeks 912
Today, there are numerous GLP-1 agonists being developed and trialed for the treatment of obesity
